Collegium Pharmaceutical
COLL
133 hedge funds and large institutions have $741M invested in Collegium Pharmaceutical in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 55 increasing their positions, 35 reducing their positions, and 28 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 35
2.11% more ownership
Funds ownership: 91.97% → 94.08% (+2.1%)
4% less capital invested
Capital invested by funds: $775M → $741M (-$34.4M)
5% less funds holding
Funds holding: 140 → 133 (-7)
21% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 28
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
48% less call options, than puts
Call options by funds: $1.27M | Put options by funds: $2.46M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$10.4M |
| 2 |
Millennium Management
New York
|
+$8.18M |
| 3 |
BlackRock
New York
|
+$6.7M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$5.74M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$5.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$7.83M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$6.64M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$3.8M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.79M |
| 5 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
-$3.73M |
COLL Hedge Fund Activity: Q2 2018 in Review
133 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q2 2018, worth a combined $741M — down 4.4% from $775M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of COLL and 22 opened new positions — a net loss of 6 holders — while 35 trimmed existing stakes and 55 added.
The largest buyer was Maverick Capital, opening a new position worth an estimated $10.4M. The largest seller was Citadel Advisors, cutting an estimated $7.83M.
- 133 institutional investors held Collegium Pharmaceutical (COLL) as of Q2 2018, down from 140 in Q1 2018.
- Funds reported $741M of Collegium Pharmaceutical stock for Q2 2018, down 4.4% quarter-over-quarter.
- 22 funds opened new Collegium Pharmaceutical positions in Q2 2018 and 28 closed out, a net change of -6 holders.
- The largest Collegium Pharmaceutical buyer in Q2 2018 was Maverick Capital, an estimated $10.4M added.
- The largest Collegium Pharmaceutical seller in Q2 2018 was Citadel Advisors, an estimated $7.83M sold.
Based on aggregated 13F filings for Q2 2018.